Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 1, 2006American Journal of Clinical PathologyOpen Access

Rituximab Can Be Combined With Daily Plasma Exchange to Achieve Effective B-Cell Depletion and Clinical Improvement in Acute Autoimmune TTP

View Full Paper
Ask AI
Bookmark
Share

Authors

KDKamran DarabiRidgeview Medical CenterABAnders H. BergCedars-Sinai Medical Center

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Darabi et al. (2006) studied this question.

synapsesocial.com/papers/6aa53696bc2c7db7488e357fhttps://doi.org/10.1309/rlnmj01wbjrnlh03
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab2002 · 128 citations
  2. 2IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma1997 · 157 citations
  3. 3Structure of von Willebrand Factor-cleaving Protease (ADAMTS13), a Metalloprotease Involved in Thrombotic Thrombocytopenic Purpura2001 · 848 citations
  4. 4IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma1997 · 1,712 citations
  5. 5Assay of von Willebrand Factor (vWF)-cleaving Protease Based on Decreased Collagen Binding Affinity of Degraded vWF1999 · 301 citations